Navigation Links
ThalesNano Inc. and sanofi-aventis R&D Collaborate on Continuous Process Chemistry in Order to Dramatically Reduce Drug Realization Time

BUDAPEST, LONDON and PRINCETON, New Jersey, May 22 /PRNewswire/ -- ThalesNano Inc. and sanofi-aventis R&D today announced the signing of a research and development collaboration agreement focusing on continuous process chemistry technologies.

The collaboration will focus on the development and implementation of continuous process technologies from research to full-scale production. The purpose of the project is to study the utilization and application of ThalesNano's integrated continuous process chemistry technologies within the sanofi-aventis drug R&D process from discovery to API production.

"We are delighted to work with sanofi-aventis R&D who have always been at the forefront of applying new methods and technologies to improve the drug discovery and development process," said Dr. Laszlo Urge, CEO of ThalesNano Inc. "The ThalesNano continuous process technology is already well established in the discovery labs of the life sciences industry. Taking it to process scale promises tremendous benefits for our customers in terms of reducing development time, increasing cost efficiency and minimizing environmental impact."

Dr. Christophe Daubie, head of Chemical Development for Paris area at sanofi-aventis R&D said: "this collaboration is important also because it enters into the scope of sanofi-aventis R&D strategy in terms of our constant involvement in safety considerations, quality improvement of our processes with respect to Environmental and Industrial Hygiene aspects, including Green Chemistry."

Dr. Ferenc Darvas, President and chairman of ThalesNano Inc. said. "The benefits of continuous process chemistry over conventional batch chemistry includes the rapid synthesis of organic compounds, in particular under until now unrealizable hazardous reaction conditions. Further benefits include Green Chemistry by minimizing waste, energy consumption and raw material use, lab automation, and rapid scale-up from mg to kg quantities, which reduces CAPEX and OPEX while speeding time to market."

For more information please go to:

About ThalesNano Inc.:

ThalesNano is a world-leading provider of continuous process chemistry instruments in the rapidly developing market of laboratory and process scale flow reactors. The company has the widest portfolio of bench-top continuous process instruments. Its R&D 100 award winning H-Cube(R) continuous-flow hydrogenation reactor and the pilot plant scale version H-Cube Midi(TM) are used in hundreds of laboratories in four continents and have become the new industry standard for hydrogenation.

About Sanofi-Aventis:

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone.

SOURCE Thalesnano Nanotechnology Inc
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ThalesNano Inc. Opens Own Representation in the United Kingdom and has New Distribution Agreements for Europe and India
2. Sanofi-aventis SoloSTAR(R) Insulin Pen for Lantus and Apidra Receives the Prestigious GOOD DESIGN Award
3. Shareholder Class Action Filed Against Sanofi-Aventis by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
4. Sanofi-aventis Announces Settlement of Average Wholesale Price Civil Suits With the U.S. Department of Justice Relating to Anzemet(R)
5. Caliper Life Sciences and DiscoveRx Collaborate to Offer Solutions for Cell-Based GPCR Profiling and Lead Optimization
6. Fred Hutchinson Cancer Research Center and NSB POSTECH, Inc. to Collaborate on Development of New Class of Proteomic Microarrays
7. ProMetic and Sartorius Stedim Biotech collaborate on technology transfer deals in Asia
8. Singulex Collaborates With Large Pharmaceutical Company in Erenna(TM) Technology Access Program
9. NIH collaborates with EPA to improve the safety testing of chemicals
10. GeneGo Collaborates With The Netherlands Toxicogenomics Center on $100 Million Grant
11. DuPont and Precision BioSciences Collaborate to Accelerate Crop Product Development
Post Your Comments:
(Date:11/27/2015)... November 27, 2015 ... popularity of companion diagnostics is one of ... market with pharmaceutical companies and diagnostic manufacturers ... tests. . --> ... report on global cancer biomarkers market spread ...
(Date:11/25/2015)... 2015  PharmAthene, Inc. (NYSE MKT: PIP) announced  today ... rights plan (Rights Plan) in an effort to preserve ... under Section 382 of the Internal Revenue Code (Code). ... use of its NOLs could be substantially limited if ... Section 382 of the Code. In general, an ownership ...
(Date:11/25/2015)... Nov. 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... President and CEO of Neurocrine Biosciences, will be presenting ... New York . ... website approximately 5 minutes prior to the presentation to ... the presentation will be available on the website approximately ...
(Date:11/25/2015)... PORTLAND, Oregon , November 25, 2015 /PRNewswire/ ... Deep Market Research Report is a professional and ... Genomics industry.      (Logo: ... basic overview of the industry including definitions, classifications, ... analysis is provided for the international markets including ...
Breaking Biology Technology:
(Date:10/29/2015)... Va. , Oct. 29, 2015 Daon, ... today that it has released a new version of ... customers in North America have ... IdentityX v4.0 also includes a FIDO UAF certified ... are already preparing to activate FIDO features. These customers ...
(Date:10/29/2015)... 29, 2015 Today, LifeBEAM , ... with 2XU, a global leader in technical performance ... hat with advanced bio-sensing technology. The hat will ... monitor key biometrics to improve overall training performance. ... two companies will bring together the most advanced technology, ...
(Date:10/26/2015)... , October 26, 2015 ... --> adds Biometrics Market ... 2021 as well as Emerging Biometrics ... reports to its collection of IT ... . --> ...
Breaking Biology News(10 mins):